Munoz Science City, Nueva Ecija,
The Philippines
March 5, 2005
By Lyn Resurreccion, Science
Editor, Philippines
TODAY via SEARCA BIC
Gone are the days when Filipino scientists and researchers
engage only in research and development (R&D); when they are not
conscious of the business aspects of their projects. With the
advent of modern agricultural biotechnology, where organisms are
altered or improved to make them suit the modern man's needs,
and with the borderless trade, government researchers and
scientists are now becoming conscious of protecting their
intellectual creation so that they and their respective agencies
could take full advantage of their intellectual property (IP) --
especially commercially.
At the same time, they are now also asserting their rights when
using foreign IPs -- also to be able to gain from their market
potential.
"We are becoming very conscious [about IP] because we can also
register microorganisms, so that the process of violating them
[researchers' IP rights, or IPRs] could be prevented," said
lawyer Ronilo Beronio, deputy executive director of the
Philippine Rice Research
Institute (PhilRice) in Muñoz Science City in Nueva Ecija
and concurrent head of its Intellectual Property Management
Office (IPMO).
He explained that he is convinced that biotech is almost
synonymous with IPR. "When you make an invention or a creation,
that organism shall become intellectual property because it
becomes intellectual creation. It is almost a one-to-one
correspondence."
He told Today in an interview that researchers and scientists at
PhilRice are now becoming aware of the measures in applying
foreign biotechnology into the Philippine setting, especially
with the prospect of possibly using it commercially.
"Before you can use a [biotech] technique, you have to seek
permission from the owners, particularly if you would wish to
make money out of it or commercialize it. . . If you want to
make money from biotech [products], their owners will run after
you, so you should be conscious about [the measures needed]," he
said.
He said that PhilRice, an agency under the Department of
Agriculture, is not yet encountering problems on the matter
because it is still in R&D stage of some technologies. But this
early, the agency is not only becoming conscious about IPR
"because we don't want to encounter problems [in the future]."
It is also "doing something" about it.
"There are many instances in the world, when scientists do
something, but in the end they could not commercialize their
products because they did not take care of the IP issues
beforehand."
Negotiations
The liberalization of trade with the advent of GATT-WTO with its
Trade Related Intellectual Property Rights, or TRIPS, has
altered international trade and IP landscape.
"Ang target lang nila noon IPs on computer software, movies and
the like. Then came agricultural biotech, which is becoming
pervasive," Beronio said.
He cited the case of Vitamin A Rice, which is being tested in
PhilRice. The agency was not yet conscious of IP implications
when it first signed the testing agreement. Realizing this,
PhilRice is renegotiating the license with the consortium, led
by Europe-based agribusiness company Syngenta, that owns the
biotechnology.
The problem? The agreement had "no clear provision" that would
allow PhilRice to commercialize. "There was a very limited
authority to commercialize" the genetically modified crop, also
popularly known as Golden Rice. Under the original agreement,
Syngenta allows an individual farmer or seed grower to
commercialize the Vitamin A Rice seeds up to $10,000 (or
approximately P550,000) as the company's so-called humanitarian
target.
Beronio gave a hypothetical situation: If PhilRice will organize
100 seed growers to produce seeds, which production may exceed
$10,000, will the agency be exempted from paying royalty?
This prompted PhilRice to renegotiate to insert a provision that
will allow it to commercialize, or what is known in the IP lingo
as "option to license agreement."
"If the Vitamin A Rice becomes a hit and becomes very critical
to our food and nutrition, we don't want to be placed in a
situation, when that's the only time we deal with it, which is
already too late because the owners may also be conscious about
the commercial prospects of the product. So, this early, we
should both take the risk of [the test's] failure, as well as
success," Beronio said.
He noted, however, that Syngenta has earlier said that it has
"no commercial interest" for the crop in the country.
He said that the result of the renegotiation on the license
agreement on Vitamin A Rice will be concluded soon.
Similarly, in the recent plan to adopt Bt cotton in the
Philippines, Beronio said his office has helped in injecting the
provision on the option for commercialization in the licensing
agreement with the Chinese owners of the genetically modified
organism.
"Whatever happens [to the adoption of the transgenic crop in the
country] you know what you will do. Kung mag-fail, sorry; kung
mag-succeed alam mo na at ng Chinese ang relationship ninyo."
IPR is not very complicated, he said. "Isang phrase lang 'yon sa
contract tapos na ang usapan."
He also cited important Philippine products, whose IPs were not
pursued, leaving the country failing to profit from them
financially, or even losing the right to a product.
One is the virgin coconut oil, which, he said, is "exploding in
the market, and nobody seems to be controlling it."
Another is the nata de coco, once a very popular traditional
Filipino delicacy. Thailand is benefiting from it and is reaping
a windfall by exporting the product to Japan because the
Philippines did not protect its technology.
He stressed that the IP owners "appreciate" it when the
licensees insist on their rights "because that would also
prevent problems and embarrassments for them in the future. . .
These countries will respect you if you negotiate with them. You
should assert [your rights]."
Beronio warned that the Philippines will be left behind in
biotechnology if it will not be serious in its IPRs. "In many
biotechnology ventures, we were already left behind."
Citing cotton, he said the Philippine cotton is just as big as
golf balls, while the Bt cotton of China is as big as the
baseball.
There is also an even more advanced development in IP -- the
Canadian Supreme Court's recent decision on plant biotech, which
says that the right of the person who inserted the gene to the
plant extends to the new plant itself.
"There is no dividing line now between the patent and the plant
protection. Dahil may na-introduce na siya [researcher] sa
plant, kahit iba ang mag-breed [sa plant] sa kanya [researcher]
'na yun [right to the plant]," Beronio said.
Training
To be able to develop the skills and capabilities among DA
researchers and scientists on IP matters, the IPMO is providing
them training. PhilRice is the only R&D institution in the DA
that has an IP policy in place.
"I tell the [nonlegal] staff, 'I'm making patent lawyers out of
you,'" Beronio said in jest.
Actually, Beronio has been training his IPMO staff in filling up
patent registration forms, training them in licensing agreements
and in assisting the scientists in filing up the forms and
entering into licensing agreements.
"We need this kind of [human capability] investment. If you let
law firms handle your [patent] registrations, they will bill you
by the minute." He clarified that if members of the staff are
well trained on IP concerns, lawyers are needed only when there
are legal contests.
The P1.2-million project, funded by DA's Biotech Program and
PhilRice, will have five batches of training this year.
It includes lectures and exercises on the fundamentals of IP,
patent searching drafting of claims, IP valuation, and IP
commercialization and technology transfer.
Fundamentals of IP: It involves orientation on the
definition, history, existing national and international IP laws
and regulations, basic information on patents, utility models,
copyright, plant variety protection, layout designs,
geographical indications, and term of protection.
Patent searching: A technique in IP audit, patent search
could be easily made through the Internet. Through the
technique, Beronio said, a researcher can access 80 percent of
the inventions worldwide through the Internet by using codes.
From this the researcher could check if the concept he wants to
develop is already available abroad. If it does, he should turn
to new ideas for research, or just modify the foreign research
for Philippine setting.
"If we are able to institutionalize patent search [among
researchers] we can save our meager funds in the government
because researchers won't do a research all over again. They can
concentrate on breakthrough or cutting-edge researches," Beronio
said.
Drafting of claims: The training on the drafting of
claims, he said, is also very critical. He said there is a
peculiar language used, which only patent lawyers know, in
filing patent claims, in reacting against another patent and in
arguing for one's claims.
Training participants will be taught on the process in drafting
claims and the specification for patent applications on
engineering and biotechnology. Real life experiences will be
shared to them and they will be given practical exercises.
IP valuation: Through IP valuation, its owner can decide
on the most effective way in which it may be used, protected,
insured, sold, leveraged or exchanged in the market. The
training will focus on reviewing situations why IP valuation is
necessary, the different methods of valuing IP and the uses and
limitations of each.
IP commercialization and technology transfer: The
training proposal said that one of the main advantages of clear
IPRs is that it facilitates technology transfer through
licensing, strategic alliances and other types of contractual
arrangements. It added that it is important for research
institutions to have an effective knowledge on IP
commercialization and technology transfer so that "it can fully
reap the benefits of its IP."
The training will include handling technology-transfer
agreements, such as licensing, material-transfer,
confidential-disclosure and other related agreements.
IPRs made
Beronio said that the less than one-year-old IPMO has registered
seven patents and has paid the Filipino researchers royalties
for their inventions, mostly machinery.
The royalty arrangement is 60-40 in favor of the scientist, if
the invention was an initiative of the scientist, even if the
facilities and funds used were that of PhilRice, and 40-60 in
favor of PhilRice, if it was the agency's initiative.
Among those up for patent registration is the PhilRice and
University of the Philippines Diliman project on canned rice
with adobo or menudo. An exclusive licensing agreement was
already entered into with a private company to market the
product.
PhilRice is also negotiating for an agreement on the use of a
transgenic bacterial leaf blight-resistant rice owned by the
University of California and for another gene against tungro
with Danforth Laboratory in the US.
Raging debate
A raging debate is ongoing which could revolutionize the IP
landscape in the country. The issue: whether IPs made by
Philippine government institutions and scientists using public
funds and facilities should be protected and be made available
for licensing agreements for commercialization, or whether these
should be given free to farmers or consumers because they are
publicly generated anyway.
Obviously, the science community is in favor of the former.
Beronio asked, "How will you encourage innovation and invention
in the public sector? You should provide some incentives. You
cannot provide incentives without commercialization because how
will you generate royalties?"
He explained that commercialization does not simply mean giving
the technology to the farmers for free, and letting them decide
whether to adopt it or not.
"When I talk about commercialization, I mean licensing
agreements; [giving] exclusivity to commercial companies, who
will have a certain degree of monopoly. No businessman in his
right mind will buy a technology from the government if he knows
that he has many competitors."
A patent is protected for 20 years, which gives the businessman
a limited monopoly with his exclusive licensing agreement. While
the businessman is ensured of making money, the patent owner
collects royalties from him.
"Where will you get royalties? [The government] cannot
appropriate it. We only get it from commercialization. But if we
won't allow such arrangement, paano kikita ang researcher? Kasi
[it is for] public good [and should be given for free]? This is
the reason why the government is not earning."
To stress his point, Beronio explained that the US has been
profiting from this system since the 1980s through the Bayh-Dole
Act. The law allows universities and public institutions to
commercialize their IPs, even if they were generated from
federal grants. It even allows the inventors to spin-off in
private business, making the scientists earn, if not become
rich, from their intellectual creation.
"Ang nangyari na-revolutionize ang landscape sa universities [in
the US], na-encourage ang mga scientists, na-unleash ang
kanilang creativity," he said, citing that Columbia University
in the US has been earning a whopping $1 billion a year from the
drugs its scientists help develop.
He added that if the publicly owned IPs are bid out, their
owners will be free from perceived corruption and conflict of
interest issue when they help businessmen trade their product.
Beronio suggested that one way to cut the budget deficit in the
Philippines is by allowing government research agencies and
universities earn and let their income revolve within the
institution. Actually, the funds generated by almost all
government research agencies or educational institutions from
royalties or sales go to the National Treasury and not for the
use of the agencies and their scientists and
researchers.Fortunately, PhilRice is allowed to revolve the fund
it gets from sales and royalties.
Another scientist told Today that many government researchers
and scientists have left their public posts for greener pastures
in private research agencies or go abroad, owing to lack of
incentive from the government.
On the argument on government researchers' IP are for public
good and therefore should be given free to the consumers,
Beronio said that the science community is not only dealing with
public good now. "Public good has international dimensions.
Vitamin A Rice is 50 percent public good and 50-percent
international good. So that definition of public good is getting
blurred now. It is no longer fully public. There is private
component in it."
He said they are conscious that IP protection should not hinder
the promotion of the technology.
He explained: "The focus of protection is to prevent
misappropriation by others. Protection simply gives us
confidence that we are really the owners. That we shall be able
to selectively engage the market, hindi lang free for all. When
people think about public good, I think they generally mean
free. Kahit ang magsasaka ayaw na ng libre. Kung ako ang
magsasaka bibilhin ko, bibigyan ko kayo ng royalty, basta
maganda ang quality ng product mo."
He said the DA and Department of Science and Technology are into
a one-year study on the available legal and institutional
frameworks on the issue in the country.
He said the matter should have a definite legal ground. "We are
in a tightrope. We are doing a balancing act. Anybody can
challenge it. So I say, 'Go ahead challenge it [in court], so
that the Supreme Court can resolve the issue.'" Or a law might
be needed to settle its legality.
He said that while the issue has become very controversial, it
also "generates a lot of rights and protection for the farmers.
Because this time we are selling a product and we are liable
under the Consumer Act for any failure on our part. So [the
farmers can say], 'While you [IP owner] are protected, I'm also
protected because now I can sue you for selling me a bad
product.'" |